Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

New platform to set standards in plant tissue culture

Nxt Bioscience has recently completed the acquisition of Lowes TC and introduced the AX Technology Platform. This move aims not only to broaden the company's portfolio but also to set standards in plant tissue culture.

Lowes TC, established by scientist Greg Lowe, has been pioneering tissue culture technologies. Notably, the company's AXR and AXL systems, have automated the tissue culture process which allows for the production of 2,000 to 5,000 plant tissue culture (PTC) plants per hour. The company claims that these innovations doubled efficiency while reducing costs.

"The merger with Lowes TC brings a fusion of expertise, innovation, and resources under the Nxt Bioscience banner. Spearheaded by founder and CEO, Daniel Mansfield, we aim to fast-track the growth and market presence of both the AX and TC+ technology platforms. These platforms are engineered to democratize plant tissue culture technology, particularly beneficial for regions with higher labor costs, rendering these innovations more viable and sustainable," says the company's team.

The AX technology is developed through research and supported by Australian Government funding towards the goal of shifting plant tissue culture practices. Coupled with the TC+ Bioreactors, an automated, pressure-controlled system, NXT Bioscience aims to cut labor expenses and improve efficiency across the industry.


AX machine in clean room

"This strategic acquisition and the innovation it brings highlight NXT Bioscience's dedication to leading-edge solutions and our commitment to spearheading the global shift towards more sustainable agricultural practices. We are now better positioned to address the critical challenges facing the horticulture, agriculture, and bio-industry sectors, offering high-quality, virus-free plant clones on a scale never before achievable," the team adds.

Further, they invite professionals, innovators, and enthusiasts within the plant tissue culture community to join them during this journey.

For more information:
NXT Bioscience
4/167 Flinders Lane,
Melbourne VIC 3000
Australia
Tel. +61 1300 000 000
[email protected]

Publication date: